Envoy Medical Inc. announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has reached the midway point of its full enrollment target. The company reports that enrollment is progressing steadily and remains on track for completion within the first half of the first quarter of 2026. The Acclaim® cochlear implant is designed to utilize a proprietary implanted piezoelectric sensor to capture sound through the natural ear, rather than relying on an external microphone. Results from the pivotal study have not yet been presented and are expected to be available following the completion of enrollment and subsequent phases of the trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 278490) on December 18, 2025, and is solely responsible for the information contained therein.